MONTPELLIER, France–(BUSINESS WIRE)–Regulatory Information:
Sensorion (FR0012596468 “ ALSEN) a pioneering clinical-stage biotechnology firm which specializes within the improvement of novel therapies to revive, deal with and forestall throughout the area of listening to loss problems, introduced right now that it’ll current on the forty third Annual J.P. Morgan Healthcare Convention, San Francisco, USA, to be held on January 13-16, 2025.
Nawal Ouzren, Chief Government Officer of Sensorion, will make a presentation on January 16, 2025, at 9am PT (6pm CET). A Q&A session will observe the presentation.
A reside webcast of Sensorion’s presentation can be out there on the Firm’s web site (https://www.sensorion.com/en/). A replay of the webcast can be out there on the Firm’s web site for about 30 days.
About Sensorion
Sensorion is a pioneering clinical-stage biotech firm, which specializes within the improvement of novel therapies to revive, deal with, and forestall listening to loss problems, a big world unmet medical want. Sensorion has constructed a novel R&D expertise platform to increase its understanding of the pathophysiology and etiology of inside ear associated illnesses, enabling it to pick out one of the best targets and mechanisms of motion for drug candidates.
It has two gene remedy packages aimed toward correcting hereditary monogenic types of deafness, developed within the framework of its broad strategic collaboration centered on the genetics of listening to with the Institut Pasteur. SENS-501 (OTOF-GT) presently being developed in a Part 1/2 medical trial, targets deafness brought on by mutations of the gene encoding for otoferlin and GJB2-GT targets listening to loss associated to mutations in GJB2 gene to probably tackle essential listening to loss segments in adults and youngsters. The Firm can also be engaged on the identification of biomarkers to enhance prognosis of those underserved diseases.
Sensorion’s portfolio additionally includes clinical-stage small molecule packages for the remedy and prevention of listening to loss problems. Sensorion’s clinical-stage portfolio contains one Part 2 product: SENS-401 (Arazasetron) progressing in a deliberate Part 2 proof of idea medical examine of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with companion Cochlear Restricted, has accomplished in a examine of SENS-401 in sufferers scheduled for cochlear implantation. A Part 2 examine of SENS-401 was additionally accomplished in Sudden Sensorineural Listening to Loss (SSNHL) in January 2022.
www.sensorion.com
Label: SENSORION
ISIN: FR0012596468
Mnemonic: ALSEN
Disclaimer
This press release incorporates sure forward-looking statements regarding Sensorion and its enterprise. Such ahead wanting statements are primarily based on assumptions that Sensorion considers to be affordable. Nonetheless, there might be no assurance that such forward-looking statements can be verified, which statements are topic to quite a few dangers, together with the dangers set forth within the 2023 full 12 months report revealed on March 14, 2024, and out there on our web site and to the event of financial situations, monetary markets and the markets by which Sensorion operates. The forward-looking statements contained on this press release are additionally topic to dangers not but recognized to Sensorion or not presently thought of materials by Sensorion. The prevalence of all or a part of such dangers may trigger precise outcomes, monetary situations, efficiency or achievements of Sensorion to be materially totally different from such forward-looking statements. This press release and the knowledge that it incorporates don’t represent a proposal to promote or subscribe for, or a solicitation of a proposal to buy or subscribe for, Sensorion shares in any nation. The communication of this press release in sure international locations might represent a violation of native legal guidelines and laws. Any recipient of this press release should inform oneself of any such native restrictions and comply therewith.
View supply model on businesswire.com: https://www.businesswire.com/information/dwelling/20241202663298/en/
Investor Relations
Noémie Djokovic, Investor Relations and Communication Affiliate
ir.contact@sensorion-pharma.com
Press Relations
Ulysse Communication
Bruno Arabian / 00 33(0)6 87 88 47 26
barabian@ulysse-communication.com
Nicolas Entz / 00 33 (0)6 33 67 31 54
nentz@ulysse-communication.com
Supply: Sensorion